DrugCite
Search

CLINDAMYCIN PHOSPHATE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Clindamycin Phosphate Adverse Events Reported to the FDA Over Time

How are Clindamycin Phosphate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Clindamycin Phosphate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Clindamycin Phosphate is flagged as the suspect drug causing the adverse event.

Most Common Clindamycin Phosphate Adverse Events Reported to the FDA

What are the most common Clindamycin Phosphate adverse events reported to the FDA?

Diarrhoea
477 (2.05%)
Pyrexia
362 (1.56%)
Rash
340 (1.46%)
Nausea
292 (1.26%)
Dyspnoea
275 (1.18%)
Pruritus
236 (1.01%)
Vomiting
224 (.96%)
Erythema
185 (.8%)
Drug Ineffective
180 (.77%)
Dizziness
170 (.73%)
Drug Interaction
158 (.68%)
Show More Show More
Renal Failure Acute
156 (.67%)
Headache
154 (.66%)
Drug Hypersensitivity
144 (.62%)
Fatigue
142 (.61%)
Asthenia
140 (.6%)
Abdominal Pain
136 (.58%)
Urticaria
132 (.57%)
Pneumonia
128 (.55%)
Neutropenia
123 (.53%)
Hypotension
121 (.52%)
Ageusia
118 (.51%)
Hypersensitivity
118 (.51%)
Abdominal Pain Upper
113 (.49%)
Chest Pain
113 (.49%)
Chills
112 (.48%)
Pain
112 (.48%)
Clostridium Difficile Colitis
107 (.46%)
Dehydration
104 (.45%)
Sepsis
103 (.44%)
Malaise
102 (.44%)
Pancytopenia
97 (.42%)
Clostridial Infection
96 (.41%)
Drug Rash With Eosinophilia And Sys...
92 (.4%)
Multi-organ Failure
91 (.39%)
Anaemia
90 (.39%)
Aspartate Aminotransferase Increase...
90 (.39%)
Alanine Aminotransferase Increased
88 (.38%)
Swelling Face
88 (.38%)
Infection
87 (.37%)
Thrombocytopenia
86 (.37%)
Liver Disorder
82 (.35%)
Stevens-johnson Syndrome
82 (.35%)
Oedema Peripheral
80 (.34%)
Renal Impairment
80 (.34%)
Toxic Epidermal Necrolysis
80 (.34%)
Condition Aggravated
79 (.34%)
Dysphagia
78 (.34%)
Renal Failure
78 (.34%)
Rash Generalised
77 (.33%)
Tachycardia
75 (.32%)
Drug Eruption
74 (.32%)
Weight Decreased
73 (.31%)
Septic Shock
72 (.31%)
Skin Exfoliation
70 (.3%)
Arthralgia
69 (.3%)
Rash Maculo-papular
69 (.3%)
Cardiac Arrest
67 (.29%)
Loss Of Consciousness
67 (.29%)
Toxic Skin Eruption
67 (.29%)
Burning Sensation
65 (.28%)
Platelet Count Decreased
65 (.28%)
Pseudomembranous Colitis
63 (.27%)
Rash Erythematous
63 (.27%)
Feeling Abnormal
62 (.27%)
Cough
61 (.26%)
Acute Generalised Exanthematous Pus...
60 (.26%)
Interstitial Lung Disease
60 (.26%)
Dysgeusia
59 (.25%)
Febrile Neutropenia
59 (.25%)
Muscle Spasms
59 (.25%)
Blister
57 (.25%)
Confusional State
57 (.25%)
Jaundice
57 (.25%)
Syncope
57 (.25%)
Rash Pruritic
55 (.24%)
Dyspepsia
54 (.23%)
Somnolence
54 (.23%)
White Blood Cell Count Decreased
54 (.23%)
Back Pain
53 (.23%)
Abdominal Distension
52 (.22%)
Haematochezia
52 (.22%)
Hypertension
52 (.22%)
International Normalised Ratio Incr...
52 (.22%)
Hepatic Enzyme Increased
51 (.22%)
Respiratory Failure
51 (.22%)
Haemoglobin Decreased
50 (.21%)
Staphylococcal Infection
50 (.21%)
Death
48 (.21%)
General Physical Health Deteriorati...
48 (.21%)
Urinary Tract Infection
48 (.21%)
Eosinophilia
47 (.2%)
Hepatic Function Abnormal
47 (.2%)
Tremor
47 (.2%)
Atrial Fibrillation
46 (.2%)
Hyperhidrosis
46 (.2%)
Insomnia
46 (.2%)
Tinnitus
46 (.2%)
Anxiety
44 (.19%)
Chest Discomfort
44 (.19%)
Drug Exposure During Pregnancy
44 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Clindamycin Phosphate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Clindamycin Phosphate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Clindamycin Phosphate

What are the most common Clindamycin Phosphate adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Clindamycin Phosphate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Clindamycin Phosphate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Clindamycin Phosphate According to Those Reporting Adverse Events

Why are people taking Clindamycin Phosphate, according to those reporting adverse events to the FDA?

Product Used For Unknown Indication
971
Drug Use For Unknown Indication
800
Acne
608
Infection
262
Prophylaxis
216
Vitamin Supplementation
208
Show More Show More
Acute Myeloid Leukaemia
200
Pneumonia
180
Tooth Infection
177
Cellulitis
162
Rash
120
Alpha-1 Anti-trypsin Deficiency
113
Ill-defined Disorder
105
Tooth Abscess
98
Osteomyelitis
93
Supplementation Therapy
82
Infection Prophylaxis
80
Sinusitis
79
Hepatic Function Abnormal
78
Toxoplasmosis
72
Pyrexia
69
Localised Infection
63
Staphylococcal Infection
62
Antibiotic Prophylaxis
56
Medical Diet
56
Sepsis
55
Hepatitis C
54
Liver Disorder
53
Bacterial Infection
52
Abscess
51
Antibiotic Therapy
46
Tooth Disorder
42
Endodontic Procedure
40
Tooth Extraction
39
Dermatitis Acneiform
39
Routine Health Maintenance
38
Pneumonia Aspiration
37
Vaginal Infection
37
Erysipelas
36
Urinary Tract Infection
36
Nasopharyngitis
35
Acute Lymphocytic Leukaemia
35
Wound Infection
33
Tonsillitis
32
Burkitts Lymphoma
32
Cerebral Toxoplasmosis
32
Dementia Alzheimers Type
31
Chronic Sinusitis
30
Bronchitis
29
Vaginitis Bacterial
29
Peripheral T-cell Lymphoma Unspecif...
28

Drug Labels

LabelLabelerEffective
Clindamax LotionPharmaDerm, A division of Nycomed US Inc.15-AUG-09
Clindamycin PhosphatePhysicians Total Care, Inc.31-AUG-09
Clindamax PharmaDerm, A division of Nycomed US Inc.01-OCT-09
AcanyaDow Pharmaceuticals Sciences09-OCT-09
ClindamaxPHARMADERM. A division of Nycomed US Inc.29-OCT-09
Clindamycin PhosphatePhysicians Total Care, Inc.12-FEB-10
Cleocin TPharmacia and Upjohn Company11-MAR-10
Clindamycin PhosphateGreenstone LLC19-APR-10
CleocinPharmacia and Upjohn Company29-JUN-10
CleocinPhysicians Total Care, Inc.29-JUL-10
CleocinPharmacia and Upjohn Company29-JUL-10
Clindagel Galderma Laboratories, L.P.20-SEP-10
Clindamycin PhosphateRebel Distributors Corp23-SEP-10
Clindamycin PhosphatePhysicians Total Care, Inc.18-OCT-10
Clindacin PMedimetriks Pharmaceuticals, Inc.14-FEB-11
Clindacin PacMedimetriks Pharmaceuticals, Inc.14-FEB-11
Clindamycin PhosphatePhysicians Total Care, Inc.01-APR-11
DuacStiefel Laboratories Inc16-JAN-12
Clinda-dermPaddock Laboratoratories, LLC27-JAN-12
AcanyaCoria Laboratories01-FEB-12
EvoclinStiefel Laboratories Inc10-FEB-12
Clindamycin PhosphatePerrigo New York Inc25-FEB-12
ZianaMedicis Pharmaceutical Corp01-MAR-12
Clindamycin PhosphatePreferred Pharmaceuticals, Inc29-MAR-12
VeltinStiefel Laboratories Inc03-MAY-12
Clindamycin PhosphateE. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc.16-MAY-12
Clindamycin PhosphatePerrigo New York Inc31-MAY-12
Clindamycin PhosphateE. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc.19-JUN-12
Clindamycin PhosphatePreferred Pharmaceuticals, Inc.27-JUL-12
Clindamycin Phosphate And Benzoyl PeroxideMylan Pharmaceuticals Inc.31-JUL-12
Clindamycin PhosphateGreenstone LLC09-AUG-12
Clindamycin PhosphateLake Erie Medical DBA Quality Care Products LLC24-AUG-12
Clindamycin Phosphate And Benzoyl PeroxidePerrigo New York Inc27-AUG-12
Clindamycin - Benzoyl PeroxidePrasco Laboratories21-DEC-12
Clindamycin PhosphateVersaPharm Incorporated12-FEB-13
ClindesseTher-Rx Corporation12-APR-13

Clindamycin Phosphate Case Reports

What Clindamycin Phosphate safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Clindamycin Phosphate. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Clindamycin Phosphate.